The latest biotech news

News and Trends 7 Mar 2017

A New Transatlantic Partnership takes on Antibiotic Resistance

The Swiss biotech BioVersys and the US company Aptuit have entered a new collaboration to target antibiotic resistances. BioVersys, based in Basel, is developing small molecules that interfere with bacterial resistance mechanisms. Its current research is focused on nosocomial infections (hospital infections) and tuberculosis. To advance the development of compounds against novel targets identified by BioVersys, the company has […]

March 7, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 6 Mar 2017

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

How is biotech in Wales? We take a look at some companies based in the ‘Land of Song,’ their plans and their achievements. After taking a look at the vibrant biotech clusters in the UK like London and Cambridge and picking the top biotechs in Scotland, it’s time to direct our attention to the western part […]

March 6, 2017 - 4 minutesmins - By External Contributor

News and Trends 4 Mar 2017

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Johanna Rotko creates living art with yeast to explore the perishableness of matter and how we interact with nature around us. Johanna Rotko is a visual artist and photographer based in Kotka, Finland, that decided to explore alternative photographic methods. The result were yeastograms, living images made with yeast on petri dishes that disappear over […]

March 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

HIV vaccine University Oxford IrsiCaixa AIDS

News and Trends 3 Mar 2017

An HIV Vaccine Eliminates the Virus in a Patient for 7 Months

An HIV vaccine developed at the University of Oxford has kept 5 out of 15 patients completely free of HIV. One of the patients has already been clear for 7 months. AIDS affects over 36.7 million people. Antiretroviral therapy (ART) is the most common treatment, which kills those cells in which the virus is active. However, HIV can remain inactive and […]

March 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Mar 2017

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]

March 2, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 1 Mar 2017

Swedish Oncology Biotech makes a Large IPO for its Peptides

The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 1 Mar 2017

Scaling Up your Drug? Follow these 3 Steps to Succeed

As a biotech scales up from the lab to industry, data management is a key part of the process. Even if you manage to prove your concept, applying it to patients will increase the number of variables in the business process calculations exponentially. How do you keep track of them all? In the development of […]

March 1, 2017 - 5 minutesmins - By External Contributor

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up with Genentech to bring its amyloid beta (Aβ)-targeting antibody crenezumab into the clinic. Although the compound did not meet its co-primary enpoints in the large phase II ABBY trial, Genentech pushed […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

Arsanis Adimab RSV monoclonal antibodies

News and Trends 28 Feb 2017

New Antibodies to Target the Respiratory Syncytial Virus

The two companies Arsanis and Adimab, both specialized in the development of monoclonal antibodies, have partnered up against respiratory syncytial virus (RSV). Their license agreement is backed by the Gates Foundation. The clinical-stage biotech Arsanis is developing monoclonal antibodies (mAbs) for the treatment of serious infectious diseases. The company announced that they have gained the exclusive worldwide […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 28 Feb 2017

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

We’ve compiled a list of some of the latest advances of biotech in the field of rare disease to contribute to Rare Disease Day 2017. The European Organization for Rare Diseases (EURORDIS) is once again coordinating Rare Disease Day, which takes place on the last day of February every year. The aim is to raise awareness of […]

February 28, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

BOM Gallery Laurie Ramsell Gina Czarnecki

News and Trends 25 Feb 2017

Art Made with Human DNA Explores the Future of Genetics in Birmingham

Gene Craft: Art in the Biogenetic Age opened this week at Birmingham Open Media (BOM) in the UK. Aiming to explore the social, economic and emotional implications of the most recent breakthroughs in genetics, the exhibition features two living art pieces created with human DNA by bioartists Laurie Ramsell and Gina Czarnecki. After the Human Fertilisation and Embryology Authority (HFEA) […]

February 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Feb 2017

What are the Current Challenges in the Booming Field of ADCs?

ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the World ADC Conference to hear about current efforts. ADCs represent an exciting new field that has seen renewed interest in the past few months, as funding has poured into NBE Therapeutics and ADC Therapeutics. Theses drugs are overcoming the challenges that held the first two generations back […]

February 24, 2017 - 5 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

A New Transatlantic Partnership takes on Antibiotic Resistance

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

An HIV Vaccine Eliminates the Virus in a Patient for 7 Months

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Swedish Oncology Biotech makes a Large IPO for its Peptides

Scaling Up your Drug? Follow these 3 Steps to Succeed

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

New Antibodies to Target the Respiratory Syncytial Virus

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

Art Made with Human DNA Explores the Future of Genetics in Birmingham

What are the Current Challenges in the Booming Field of ADCs?

Subscribe to our newsletter to get the latest biotech news!